

ONE HUNDRED FOURTEENTH CONGRESS  
**Congress of the United States**  
**House of Representatives**  
COMMITTEE ON ENERGY AND COMMERCE  
2125 RAYBURN HOUSE OFFICE BUILDING  
WASHINGTON, DC 20515-6115  
Majority (202) 225-2927  
Minority (202) 225-3641

November 13, 2015

Mr. Tim Gronniger  
Director of Delivery System Reform  
Centers for Medicare and Medicaid Services  
200 Independence Avenue, N.W.  
Washington, DC 20201

Dear Mr. Gronniger:


Thank you for appearing before the Subcommittee on Health on October 21, 2015, to testify at the hearing entitled "Examining the Medicare Part D Medication Therapy Management Program."

Pursuant to the Rules of the Committee on Energy and Commerce, the hearing record remains open for ten business days to permit Members to submit additional questions for the record, which are attached. The format of your responses to these questions should be as follows: (1) the name of the Member whose question you are addressing, (2) the complete text of the question you are addressing in bold, and (3) your answer to that question in plain text.

To facilitate the printing of the hearing record, please respond to these questions with a transmittal letter by the close of business on November 27, 2015. Your responses should be mailed to Graham Pittman, Legislative Clerk, Committee on Energy and Commerce, 2125 Rayburn House Office Building, Washington, DC 20515 and e-mailed in Word format to [graham.pittman@mail.house.gov](mailto:graham.pittman@mail.house.gov).

Thank you again for your time and effort preparing and delivering testimony before the Subcommittee.

Sincerely,

  
Joseph R. Pitts  
Chairman  
Subcommittee on Health

cc: The Honorable Gene Green, Ranking Member, Subcommittee on Health

Attachment

**Attachment — Additional Questions for the Record**

**The Honorable Representative Joseph R. Pitts**

1. In response to questions posed by Ranking Member Green, you stated that if the CMS MTM model "data is strong enough and we were able to demonstrate improvements in quality, there would be opportunities to expand the model before the demonstration concludes in 2022." Understanding that the non-interference clause under Part D prevents CMS from interceding in the negotiations between pharmacists, plans, and manufacturers, would CMS need the support of new statutory authority to implement changes to the Part D MTM program? If not, could you please cite the statutory authority CMS believes it has to implement reforms under the MTM program, including the types of reforms permissible?